The presence of fat-enlarged axillary lymph nodes on mammography screening exams is associated with a fourfold higher risk of type 2 diabetes and a 2.6-fold higher risk for cardiovascular disease, according to new research presented at the ARRS Annual Meeting.
Emerging research suggests the detection of fat-enlarged axillary lymph nodes on screening mammography exams may be associated with significantly higher risks of type 2 diabetes (T2DM), cardiovascular disease (CVD), and hypertension (HTN).
In a retrospective study, which garnered Summa Cum Laude honors at the 2024 American Roentgen Ray Society (ARRS) Annual Meeting in Boston, researchers reviewed bilateral mediolateral oblique views from mammography exams for 1,216 women who had cardiovascular risk factors within one year of the mammogram but no known coronary artery disease (CAD) at the time of the mammography screening. The study authors measured the largest visible axillary lymph node and also determined if the patients had any major adverse cardiovascular events (MACEs) within 10 years after the index mammogram.
The researchers found that 19.1 percent of the cohort had fat-enlarged axillary lymph nodes (greater than 20 mm in length) due to an expanded fatty hilium. For these patients, the study authors noted a fourfold higher risk for T2DM, a 2.6-fold higher risk of CVD, and a 2.5-fold higher risk of HTN.
Here one can see a comparison between mammography findings for two women with similar body mass index (BMI). Note the normal axillary lymph nodes in a 63-year-old woman (A) and a fat-enlarged axillary lymph node in a 52-year-old woman (B). New research revealed a fourfold higher risk of type 2 diabetes and a 2.6-fold higher risk for cardiovascular disease in women presenting with fat-enlarged axillary lymph nodes on mammography exams. (Images courtesy of the American Roentgen Ray Society (ARRS).
“Fat-enlarged axillary lymph nodes visualized on screening mammography may increase the ability to identify women who would benefit from CVD risk reduction strategies and more intensive risk assessment with coronary artery CT,” suggested lead study author Jessica Rubino, M.D., who is affiliated with the Dartmouth Hitchcock Medical Center in Lebanon, N.H., and colleagues.
The researchers noted that axillary lymph nodes were visible on 907 of the 1216 mammography exams reviewed in the study (74.6 percent). Emphasizing the wide eligibility for screening mammography for over 75 percent of women in the United States, the study authors emphasized that obtaining cardiovascular risk data from mammograms could have a significant impact in reducing mortality from CVD, the leading cause of death in women.
“If validated in larger studies, incorporating fat-enlarged nodes into CVD risk models has the potential to improve CVD risk stratification without additional cost or additional testing,” posited Rubino and colleagues.
Reference
1. Rubino J, Austin-Strohbehn J, Wang Q, et al. Fat-enlarged axillary lymph nodes on screening mammograms predict cardiometabolic disease and cardiovascular disease risk. Presented at the 2024 American Roentgen Ray Society (ARRS) Annual Meeting in Boston, May 5-9, Boston. Available at: https://apps.arrs.org/MeetingPortal24/ . Accessed May 5, 2024.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.